Company intelligence / Profile preview

Hera Diagnostics

McAllen, Texas, United States

Ownership: Private
Development stage: Other

Overview

HeraFem provides real-time, non-invasive cervical cancer detection at the point-of-care with 91% sensitivity for CIN2+ lesions, enabling immediate, lab-independent diagnosis; this device improves clinical accuracy and access to care, especially in underserved regions

Therapeutic areas: Women's HealthOncology
Modalities: DeviceArtificial intelligence-based diagnostic
Industry: Digital Health Medical Devices

Partnerships

Distribution partners in Central and South America (named partners not specified)

Beyond the preview

Go deeper on Hera Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hera Diagnostics.

Explore the full profile